Andrew Kraft to Sarcoma
This is a "connection" page, showing publications Andrew Kraft has written about Sarcoma.
Connection Strength
0.316
-
Cixutumumab and temsirolimus for patients with bone and soft-tissue sarcoma: a multicentre, open-label, phase 2 trial. Lancet Oncol. 2013 Apr; 14(4):371-82.
Score: 0.105
-
Phase II study of sorafenib in patients with metastatic or recurrent sarcomas. J Clin Oncol. 2009 Jul 01; 27(19):3133-40.
Score: 0.080
-
Fatal rhabdomyolysis as a complication of ET-743 (Yondelis) chemotherapy for sarcoma. Cancer Biol Ther. 2007 Jul; 6(7):1015-7.
Score: 0.071
-
A multicenter Phase II study of bortezomib in recurrent or metastatic sarcomas. Cancer. 2005 Apr 01; 103(7):1431-8.
Score: 0.060